1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-06-24 am EDT
3570.00 JPY   +2.79%
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemophilia A
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical Logs 178% Surge in Q1 Net Income on Higher Sales

04/26/2022 | 03:43am EDT


© MT Newswires 2022
All news about CHUGAI PHARMACEUTICAL CO., LTD
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemop..
MT
06/20Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis O..
MT
06/20Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ova..
MT
06/20CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Hemlibra for Additional Indication..
PU
06/20CHUGAI PHARMACEUTICAL : Obtains Partial Change Approval for Neutrogin and Avastin Based on..
PU
06/20CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention ..
PU
06/10Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pa..
MT
06/10Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Ni..
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 185 B 8 774 M 8 774 M
Net income 2022 342 B 2 529 M 2 529 M
Net cash 2022 571 B 4 225 M 4 225 M
P/E ratio 2022 17,2x
Yield 2022 2,18%
Capitalization 5 871 B 43 454 M 43 454 M
EV / Sales 2022 4,47x
EV / Sales 2023 4,95x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 570,00 JPY
Average target price 4 639,23 JPY
Spread / Average Target 30,0%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-4.42%43 454
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202